131816-89-2

Basic information

• Product Name: 4-(9,10-didehydroergolin-8-yl)methylpiperazine-2,6-dione
• Synonyms: 4-(9,10-didehydroergolin-8-yl)methylpiperazine-2,6-dione
• CAS NO: 131816-89-2
• Molecular Formula: C19H20 N4 O2
• Molecular Weight: 336.39
• Mol File: 131816-89-2.mol
• Article Data: 1

Chemical Properties

• Boiling Point: 645.7°Cat760mmHg
• Flash Point: 344.3°C
• Appearance: /
• Density: 1.42g/cm³
• Vapor Pressure: 1.47E-16mmHg at 25°C
• Refractive Index: 1.726
• CAS DataBase Reference: 4-(9,10-didehydroergolin-8-yl)methylpiperazine-2,6-dione(CAS DataBase Reference)
• NIST Chemistry Reference: 4-(9,10-didehydroergolin-8-yl)methylpiperazine-2,6-dione(131816-89-2)
• EPA Substance Registry System: 4-(9,10-didehydroergolin-8-yl)methylpiperazine-2,6-dione(131816-89-2)

Safety Data

• Hazardous Substances Data: 131816-89-2(Hazardous Substances Data)

Usage

InChI:InChI=1/C19H20N4O2/c24-17-9-23(10-18(25)22-17)8-11-4-14-13-2-1-3-15-19(13)12(7-21-15)5-16(14)20-6-11/h1-4,7,11,16,20-21H,5-6,8-10H2,(H,22,24,25)/t11-,16-/m1/s1

Upstream product

• 229156-16-5 8β-(3,5-dioxopiperazin-1-ylmethyl)-9,10-didehydro-6-cyanoergoline 
• 5878-41-1 lysergamine 
• 107052-56-2 6-methyl-9,10-didehydro-8β-(3,5-dioxopiperazine-1-yl-methyl)-ergoline 
• 229156-15-4 N-<(9,10-didehydro-6-methylergolin-8β-yl)methyl>-iminodiacetamide 
• 229156-14-3 N-<(9,10-didehydro-6-methylergolin-8β-yl)methyl>-iminodiacetic acid diethyl ester 

Relevant articles and documents

D1 agonist and/or D2 antagonist dopamine receptor properties of a series of ergoline derivatives: A structure-activity study

A series of (3,5-dioxopiperazin-1-yl)ergoline derivatives has been synthesised and evaluated in vitro and in vivo for their dopaminergic D1 and D2 components. The structural contributions to the pharmacological profile of the ergoline skeleton, its substituents on positions 1, 2, 6, 9, and the 3,5-dioxopiperazin-1-yl portion of the molecule were examined. Structure- activity relationships within this series suggested that substitution on the ergoline skeleton in position 1 or 2 and on the 3,5-dioxopiperazin-4-nitrogen generated compounds with a spectrum of dopamine agonistic/antagonistic activity sensitive to both the nature and position of substituents.